Cochrane have produced a systematic review on Anti-IgE therapy for asthma. They found that Omalizumab was significantly more effective than placebo at increasing the numbers of patients who were able to reduce or withdraw their inhaled steroids. However, they questioned the clinical value of the mean difference in steroid consumption achieved. Omalizumab, when used as an adjunct to steroids was effective in reducing asthma exacerbations. See also .
It may be of benefit in a small group of patients with uncontrolled severe persistent allergic asthma despite optimal treatment. There is still uncertainty as to how it might fit into the stepwise management of asthma .